These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 7979292)
21. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. Miyashita N; Fukano H; Niki Y; Matsushima T J Antimicrob Chemother; 2001 Sep; 48(3):403-5. PubMed ID: 11533006 [TBL] [Abstract][Full Text] [Related]
22. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. Gnarpe J; Eriksson K; Gnarpe H Antimicrob Agents Chemother; 1996 Aug; 40(8):1843-5. PubMed ID: 8843291 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Miyashita N; Niki Y; Kishimoto T; Nakajima M; Matsushima T Antimicrob Agents Chemother; 1997 Jun; 41(6):1331-4. PubMed ID: 9174194 [TBL] [Abstract][Full Text] [Related]
24. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. Lee PI; Wu MH; Huang LM; Chen JM; Lee CY J Microbiol Immunol Infect; 2008 Feb; 41(1):54-61. PubMed ID: 18327427 [TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. Niki Y; Kimura M; Miyashita N; Soejima R Antimicrob Agents Chemother; 1994 Oct; 38(10):2296-9. PubMed ID: 7840560 [TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations. Freidank HM; Losch P; Vögele H; Wiedmann-Al-Ahmad M Antimicrob Agents Chemother; 1999 Jul; 43(7):1808-10. PubMed ID: 10390251 [TBL] [Abstract][Full Text] [Related]
27. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Roblin PM; Reznik T; Kutlin A; Hammerschlag MR Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770 [TBL] [Abstract][Full Text] [Related]
28. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Hammerschlag MR; Roblin PM Antimicrob Agents Chemother; 2000 May; 44(5):1409. PubMed ID: 10819727 [No Abstract] [Full Text] [Related]
29. [Chlamydia pneumoniae and other Chlamydia species in community-acquired pneumonia]. Ruiz Carmona M; Soler Polcar N; Torres Martí A Rev Clin Esp; 1998 Sep; 198 Suppl 1():30-4. PubMed ID: 9835771 [No Abstract] [Full Text] [Related]
30. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583 [TBL] [Abstract][Full Text] [Related]
31. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Roblin PM; Kutlin A; Hammerschlag MR Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410 [TBL] [Abstract][Full Text] [Related]
32. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Lonks JR; Medeiros AA Antimicrob Agents Chemother; 1993 Sep; 37(9):1742-5. PubMed ID: 8239578 [TBL] [Abstract][Full Text] [Related]
33. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. Martin SJ; Garvin CG; McBurney CR; Sahloff EG J Antimicrob Chemother; 2001 May; 47(5):581-7. PubMed ID: 11328768 [TBL] [Abstract][Full Text] [Related]
35. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413 [TBL] [Abstract][Full Text] [Related]
37. Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua. Matute AJ; Brouwer WP; Hak E; Delgado E; Alonso E; Hoepelman IM Int J Antimicrob Agents; 2006 Nov; 28(5):423-7. PubMed ID: 17046211 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae. Research Group of Sapporo for Pediatric Chlamydial Infections. Numazaki K; Sakamoto Y; Umetsu M; Agatsuma Y; Yamanaka T; Kogasaka R; Hiraki M; Kuniya Y; Miua J; Ukae S; Ueda D; Sato T; Chiba S Int J Antimicrob Agents; 2000 Jan; 13(3):219-22. PubMed ID: 10724028 [TBL] [Abstract][Full Text] [Related]